Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
Abnormal Proliferation02:23

Abnormal Proliferation

5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

8.9K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.9K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

3.8K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab.

Blood·2026
Same author

Potent anti-tumor activity of CD98hc-targeted antibody-drug conjugates in ovarian cancer.

Signal transduction and targeted therapy·2026
Same author

Transcriptomic profile of embryoid bodies under hypoxia at single cell level.

GigaByte (Hong Kong, China)·2026
Same author

Hypoxemia-induced TIGIT expression in obstructive sleep apnea is reversible with continuous positive airway pressure.

Frontiers in immunology·2026
Same author

Rational payload selection enables high antitumoral efficacy of an anti-EGFR antibody-drug conjugate against ovarian tumors.

Neoplasia (New York, N.Y.)·2026
Same author

The role of OSM/OSMRβ axis in shaping the tumor microenvironment favoring MASLD-related HCC immune evasion.

Hepatology (Baltimore, Md.)·2026

Related Experiment Video

Updated: Mar 10, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.4K

VCAN Is Essential for ERK5-Driven Tumorigenesis in Soft Tissue Sarcoma.

Jaime Jiménez-Suárez1, Francisco J Cimas1,2,3, José Joaquín Paricio1,4

  • 1Universidad de Castilla-La Mancha, Laboratorio de Oncología Molecular, Unidad de Medicina Molecular, Instituto de Biomedicina, Unidad Asociada de Biomedicina UCLM, Unidad Asociada al CSIC, Albacete, Spain.

International Journal of Biological Sciences
|March 9, 2026
PubMed
Summary

Extracellular matrix protein VCAN is a novel target of the ERK5 pathway in soft tissue sarcoma (STS). This ERK5/VCAN axis drives STS progression and presents a potential therapeutic target for this cancer.

Keywords:
ERK5VCANadhesionmigrationsoft tissue sarcomatranscriptomics

More Related Videos

A Patient-Derived Xenograft Model for Venous Malformation
06:51

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

5.8K
Spatial and Temporal Analysis of Active ERK in the C. elegans Germline
08:40

Spatial and Temporal Analysis of Active ERK in the C. elegans Germline

Published on: November 29, 2016

10.9K

Related Experiment Videos

Last Updated: Mar 10, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.4K
A Patient-Derived Xenograft Model for Venous Malformation
06:51

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

5.8K
Spatial and Temporal Analysis of Active ERK in the C. elegans Germline
08:40

Spatial and Temporal Analysis of Active ERK in the C. elegans Germline

Published on: November 29, 2016

10.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The ERK5 signaling pathway is increasingly recognized for its role in soft tissue sarcoma (STS) development and progression.
  • Understanding the molecular mechanisms underlying ERK5's function in STS is crucial for identifying new therapeutic strategies.

Purpose of the Study:

  • To identify novel downstream targets of ERK5 in STS.
  • To elucidate the role of VCAN (a chondroitin sulfate proteoglycan) as a mediator of ERK5-driven oncogenesis in STS.

Main Methods:

  • Utilized genetic manipulation (shRNA silencing, overexpression) and pharmacological inhibition of ERK5 in murine sarcoma models and human STS cell lines.
  • Performed transcriptomic profiling to assess VCAN's contribution to the ERK5 gene expression program.
  • Analyzed VCAN and ERK5 expression in human STS patient samples (leiomyosarcomas, undifferentiated pleomorphic sarcomas) and normal tissues.

Main Results:

  • Identified VCAN as a novel transcriptional target of ERK5, with ERK5 positively regulating VCAN expression.
  • Demonstrated that VCAN silencing phenocopies ERK5 silencing effects (impaired migration, adhesion, proliferation, tumorigenesis), while VCAN overexpression rescues these effects.
  • Found significantly elevated VCAN and ERK5 mRNA levels in human STS tissues compared to normal tissues, with a strong correlation between VCAN and ERK5 expression in specific STS subtypes.

Conclusions:

  • VCAN is a key effector in ERK5-mediated tumorigenesis and oncogenesis in soft tissue sarcomas.
  • The ERK5/VCAN signaling axis represents a promising therapeutic target for soft tissue sarcomas.